

E N R O L L E D

H. B. 2931

(BY DELEGATE(S) ASHLEY)

[Passed March 12, 2015;
in effect ninety days from passage.]

AN ACT to amend and reenact §60A-2-204 of the Code of West Virginia, 1931, as amended, relating to adding drugs to the classification of schedule I drugs.

Be it enacted by the Legislature of West Virginia:

That §60A-2-204 of the Code of West Virginia, 1931, as amended, be amended and reenacted to read as follows:

ARTICLE 2. STANDARDS AND SCHEDULES.

§60A-2-204. Schedule I.

1 (a) Schedule I shall consist of the drugs and other
2 substances, by whatever official name, common or usual name,
3 chemical name, or brand name designated, listed in this section.

4 (b) Opiates. Unless specifically excepted or unless listed in
5 another schedule, any of the following opiates, including their

6 isomers, esters, ethers, salts and salts of isomers, esters and
7 ethers, whenever the existence of such isomers, esters, ethers and
8 salts is possible within the specific chemical designation (for
9 purposes of subdivision (34) of this subsection only, the term
10 isomer includes the optical and geometric isomers):

11 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
12 phenethyl)-4-piperidinyl]—phenylacetamide);

13 (2) Acetylmethadol;

14 (3) Allylprodine;

15 (4) Alphacetylmethadol (except levoalphacetylmethadol also
16 known as levo-alpha-acetylmethadol, levomethadyl acetate, or
17 LAAM);

18 (5) Alphameprodine;

19 (6) Alphamethadol;

20 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)
21 ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-
22 (-propanilido) piperidine);

23 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)
24 ethyl-4-piperidinyl]—phenylpropanamide);

25 (9) Benzethidine;

26 (10) Betacetylmethadol;

27 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)
28 -4-piperidinyl]-N-phenylpropanamide);

29 (12) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-
30 hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-
31 phenylpropanamide);

- 32 (13) Betameprodine;
- 33 (14) Betamethadol;
- 34 (15) Betaprodine;
- 35 (16) Clonitazene;
- 36 (17) Dextromoramide;
- 37 (18) Diampromide;
- 38 (19) Diethylthiambutene;
- 39 (20) Difenoxin;
- 40 (21) Dimenoxadol;
- 41 (22) Dimepheptanol;
- 42 (23) Dimethylthiambutene;
- 43 (24) Dioxaphetyl butyrate;
- 44 (25) Dipipanone;
- 45 (26) Ethylmethylthiambutene;
- 46 (27) Etonitazene;
- 47 (28) Etoxeridine;
- 48 (29) Furethidine;
- 49 (30) Hydroxypethidine;
- 50 (31) Ketobemidone;
- 51 (32) Levomoramide;

- 52 (33) Levophenacymorphan;
- 53 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
54 piperidyl]-N-phenylpropanamide);
- 55 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
56 4- piperidiny]—phenylpropanamide);
- 57 (36) Morpheridine;
- 58 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 59 (38) Noracymethadol;
- 60 (39) Norlevorphanol;
- 61 (40) Normethadone;
- 62 (41) Norpipanone;
- 63 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
64 phenethyl)-4-piperidiny] propanamide);
- 65 (43) PEPAP (1-(2-phenethyl)-4-phenyl-4-
66 acetoxypiperidine);
- 67 (44) Phenadoxone;
- 68 (45) Phenampromide;
- 69 (46) Phenomorphan;
- 70 (47) Phenoperidine;
- 71 (48) Piritramide;
- 72 (49) Proheptazine;
- 73 (50) Properidine;

74 (51) Propiram;

75 (52) Racemoramide;

76 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
77 piperidiny]-propanamide);

78 (54) Tilidine;

79 (55) Trimeperidine.

80 (c) *Opium derivatives*. — Unless specifically excepted or
81 unless listed in another schedule, any of the following opium
82 immediate derivatives, its salts, isomers and salts of isomers
83 whenever the existence of such salts, isomers and salts of
84 isomers is possible within the specific chemical designation:

85 (1) Acetorphine;

86 (2) Acetyldihydrocodeine;

87 (3) Benzylmorphine;

88 (4) Codeine methylbromide;

89 (5) Codeine-N-Oxide;

90 (6) Cyprenorphine;

91 (7) Desomorphine;

92 (8) Dihydromorphine;

93 (9) Drotebanol;

94 (10) Etorphine (except HCl Salt);

95 (11) Heroin;

- 96 (12) Hydromorphenol;
97 (13) Methyldesorphine;
98 (14) Methyldihydromorphine;
99 (15) Morphine methylbromide;
100 (16) Morphine methylsulfonate;
101 (17) Morphine-N-Oxide;
102 (18) Myrophine;
103 (19) Nicocodeine;
104 (20) Nicomorphine;
105 (21) Normorphine;
106 (22) Pholcodine;
107 (23) Thebacon.

108 (d) *Hallucinogenic substances.* — Unless specifically
109 excepted or unless listed in another schedule, any material,
110 compound, mixture or preparation, which contains any quantity
111 of the following hallucinogenic substances, or which contains
112 any of its salts, isomers and salts of isomers, whenever the
113 existence of such salts, isomers, and salts of isomers is possible
114 within the specific chemical designation (for purposes of this
115 subsection only, the term “isomer” includes the optical, position
116 and geometric isomers):

- 117 (1) Alpha-ethyltryptamine; some trade or other names:
118 tryptamine; Monase; alpha-ethy-1H-indole-3-ethanamine; 3-(2-
119 aminobutyl) indole; alpha-ET; and AET;

120 (2) 4-bromo-2, 5-dimethoxy-amphetamine; some trade or
121 other names: 4-bromo-2,5-dimethoxy-alpha-
122 methylphenethylamine; 4-bromo-2,5-DMA;

123 (3) 4-Bromo-2,5-dimethoxyphenethylamine; some trade or
124 other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;
125 alpha- desmethyl DOB; 2C-B, Nexus;

126 (4)(A) N-(2-Methoxybenzyl)-4-bromo-2, 5-
127 dimethoxyphenethylamine. The substance has the acronym 25B-
128 NBOMe.

129 (B) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
130 ethanamine (25C-NBOMe).

131 (C) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
132 ethanamine (25I-NBOMe)

133 (5) 2,5-dimethoxyamphetamine; some trade or other names:
134 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA;

135 (6) 2,5-dimethoxy-4-ethylamphet-amine; some trade or other
136 names: DOET;

137 (7) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other
138 name: 2C-T-7);

139 (8) 4-methoxyamphetamine; some trade or other names:
140 4 - m e t h o x y - a l p h a - m e t h y l p h e n e t h y l a m i n e ;
141 paramethoxyamphetamine; PMA;

142 (9) 5-methoxy-3, 4-methylenedioxy-amphetamine;

143 (10) 4-methyl-2,5-dimethoxy-amphetamine; some trade and
144 other names: 4-methyl-2,5-dimethoxy-alpha-
145 methylphenethylamine; "DOM"; and "STP";

- 146 (11) 3,4-methylenedioxy amphetamine;
- 147 (12) 3,4-methylenedioxymethamphetamine (MDMA);
- 148 (13) 3,4-methylenedioxy-N-ethylamphetamine (also known
149 as – ethyl-alpha-methyl-3,4 (methylenedioxy)
150 phenethylamine, N-ethyl MDA, MDE, MDEA);
- 151 (14) N-hydroxy-3,4-methylenedioxyamphetamine (also
152 known as – hydroxy-alpha-methyl-3,4 (methylenedioxy)
153 phenethylamine, and – hydroxy MDA);
- 154 (15) 3,4,5-trimethoxy amphetamine;
- 155 (16) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 156 (17) Alpha-methyltryptamine (other name: AMT);
- 157 (18) Bufotenine; some trade and other names:
158 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
159 dimethylaminoethyl) -5-indolol; N, N-dimethylserotonin; 5-
160 hydroxy-N,N- dimethyltryptamine; mappine;
- 161 (19) Diethyltryptamine; sometrade and other names: N, N-
162 Diethyltryptamine; DET;
- 163 (20) Dimethyltryptamine; some trade or other names: DMT;
- 164 (21) 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 165 (22) Ibogaine; some trade and other names: 7-Ethyl-6, 6
166 Beta, 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-
167 pyrido [1', 2': 1, 2] azepino [5,4-b] indole; Tabernanthe iboga;
- 168 (23) Lysergic acid diethylamide;
- 169 (24) Marihuana;

170 (25) Mescaline;

171 (26) Parahexyl-7374; some trade or other names: 3-Hexyl -
172 1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo
173 [b,d] pyran; Synhexyl;

174 (27) Peyote; meaning all parts of the plant presently
175 classified botanically as *Lophophora williamsii* Lemaire,
176 whether growing or not, the seeds thereof, any extract from any
177 part of such plant, and every compound, manufacture, salts,
178 immediate derivative, mixture or preparation of such plant, its
179 seeds or extracts;

180 (28) N-ethyl-3-piperidyl benzilate;

181 (29) N-methyl-3-piperidyl benzilate;

182 (30) Psilocybin;

183 (31) Psilocyn;

184 (32) Tetrahydrocannabinols; synthetic equivalents of the
185 substances contained in the plant, or in the resinous extractives
186 of *Cannabis*, sp. and/or synthetic substances, immediate
187 derivatives and their isomers with similar chemical structure and
188 pharmacological activity such as the following:

189 delta-1 Cis or trans tetrahydrocannabinol, and their optical
190 isomers;

191 delta-6 Cis or trans tetrahydrocannabinol, and their optical
192 isomers;

193 delta-3,4 Cis or trans tetrahydrocannabinol, and its optical
194 isomers;

195 (Since nomenclature of these substances is not
196 internationally standardized, compounds of these structures,

197 regardless of numerical designation of atomic positions
198 covered.)

199 (33) Ethylamine analog of phencyclidine; some trade or
200 other names: N-ethyl-1-phenylcyclohexylamine, (1-
201 phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl)
202 ethylamine, cyclohexamine, PCE;

203 (34) Pyrrolidine analog of phencyclidine; some trade or
204 other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

205 (35) Thiophene analog of phencyclidine; some trade or
206 other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-
207 thienylanalog of phencyclidine; TPCP, TCP;

208 (36) 1[1-(2-thienyl)cyclohexyl]pyrrolidine; some other
209 names: TCPy.

210 (37) 4-methylmethcathinone (Mephedrone);

211 (38) 3,4-methylenedioxyprovalerone (MDPV);

212 (39) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

213 (40) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)

214 (41) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)

215 (42) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)

216 (43) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-
217 T-2)

218 (44) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]
219 ethanamine (2C-T-4)

220 (45) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)

- 221 (46) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-
222 N)
- 223 (47) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-
224 P)
- 225 (48) 3,4-Methylenedioxy-N-methylcathinone
226 (Methylone)
- 227 (49) 2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-
228 T-7, itsoptical isomers, salts and salts of isomers)
- 229 (50) 5-methoxy-N,N-dimethyltryptamine some trade or other
230 names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-
231 DMT(5-MeO-DMT)
- 232 (51) Alpha-methyltryptamine (other name: AMT)
- 233 (52) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-
234 MeO-DIPT)
- 235 (53) Synthetic Cannabinoids as follows:
- 236 (A) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-
237 yl)phenol {also known as CP 47,497 and homologues};
- 238 (B) rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-
239 methylnonan-2-yl)phenol {also known as CP 47,497-C8
240 homolog};
- 241 (C) [(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
242 methyloctan-2-yl)-6a, 7,10,10a-tetrahydrobenzo[c]chromen-1-
243 ol)] {also known as HU-210};
- 244 (D) (dexanabinol); (6aS,10aS)-9-(hydroxymethyl)-6,6-
245 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzol
246 [c]chromen-1-ol) {also known as HU-211};

247 (E) 1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-
248 018};

249 (F) 1-Butyl-3-(1-naphthoyl)indole {also known as JWH-
250 073};

251 (G) (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-
252 methanone {also known as JWH-015};

253 (H) (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone
254 {also known as JWH-019};

255 (I) [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-
256 naphthalenyl-methanone {also known as JWH-200};

257 (J) 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-
258 ethanone {also known as JWH-250};

259 (K) 2 - ((1 S , 2 S , 5 S) - 5 - h y d r o x y - 2 - (3 -
260 hydroxypropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol {also
261 known as CP 55,940};

262 (L) (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -
263 methanone {also known as JWH-122};

264 (M) (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -
265 methanone {also known as JWH-398};

266 (N) (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone
267 {also known as RCS-4};

268 (O) 1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-
269 methoxyphenyl) ethanone {also known as RCS-8};

270 (P) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);

271 (Q) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
272 and

- 273 (R) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
- 274 (54) Synthetic cannabinoids or any material, compound,
275 mixture or preparation which contains any quantity of the
276 following substances, including their analogues, congeners,
277 homologues, isomers, salts and salts of analogues, congeners,
278 homologues and isomers, as follows:
- 279 (A) CP 47,497 AND homologues, 2-[(1R,3S)-3-
280 Hydroxycyclohexyl]-5-(2-methyloctan-2-YL)phenol];
- 281 (B) HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,
282 6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
283 10A-tetrahydrobenzo[C]chromen-1-OL];
- 284 (C) HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-
285 6,6-Dimethyl-3-(2-methyloctan-2-YL)-
286 6A,7,10,10atetrahydrobenzo[C]chromen-1-OL);
- 287 (D) JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
- 288 (E) JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
- 289 (F) JWH-073, 1-butyl-3-(1-naphthoyl)indole;
- 290 (G) JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)-
291 Naphthalen-1-ylmethanone;
- 292 (H) JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]
- 293 (55) Synthetic cannabinoids including any material,
294 compound, mixture or preparation that is not listed as a
295 controlled substance in Schedule I through V, is not a federal
296 Food and Drug Administration approved drug or used within
297 legitimate and approved medical research and which contains
298 any quantity of the following substances, their salts, isomers,
299 whether optical positional or geometric, analogues, homologues

300 and salts of isomers, analogues and homologues, unless
301 specifically exempted, whenever the existence of these salts,
302 isomers, analogues, homologues and salts of isomers, analogues
303 and homologues if possible within the specific chemical
304 designation:

305 (A) Tetrahydrocannabinols meaning tetrahydrocannabinols
306 which are naturally contained in a plant of the genus cannabis as
307 well as synthetic equivalents of the substances contained in the
308 plant or in the resinous extractives of cannabis or synthetic
309 substances, derivatives and their isomers with analogous
310 chemical structure and or pharmacological activity such as the
311 following:

312 (i) DELTA-1 CIS OR trans tetrahydrocannabinol and their
313 Optical isomers.

314 (ii) DELTA-6 CIS OR trans tetrahydrocannabinol and their
315 optical isomers.

316 (iii) DELTA-3,4 CIS or their trans tetrahydrocannabinol and
317 their optical isomers.

318 (B) Naphthoylindoles or any compound containing a 3-(1-
319 Naphthoyl) indole structure with substitution at the nitrogen atom
320 of the indole ring whether or not further substituted in the indole
321 ring to any extent and whether or not substituted in the naphthyl
322 ring to any extent. This shall include the following:

323 (i) JWH 015;

324 (ii) JWH 018;

325 (iii) JWH 019;

326 (iv) JWH 073;

327 (v) JWH 081;

328 (vi) JWH 122;

329 (vii) JWH 200;

330 (viii) JWH 210;

331 (ix) JWH 398;

332 (x) AM 2201;

333 (xi) WIN 55,212.

334 (56) Naphthylmethyloindoles or any compound containing a
335 1-indol-3-yl-(1-naphthyl) methane structure with a substitution at
336 the nitrogen atom of the indole ring whether or not further
337 substituted in the indole ring to any extent and whether or not
338 substituted in the naphthyl ring to any extent. This shall include,
339 but not be limited to, JWH 175 and JWH 184.

340 (57) Naphthoylpyrroles or any compound containing a 3-(1-
341 Naphthoyl) pyrrole structure with substitution at the nitrogen
342 atom of the pyrrole ring whether or not further substituted in the
343 pyrrole ring to any extent and whether or not substituted in the
344 naphthyl ring to any extent. This shall include, but not be limited
345 to, JWH 147 and JWH 307.

346 (58) Naphthylmethylindenes or any compound containing a
347 Naphthylideneindene structure with substitution at the 3-
348 Position of the indene ring whether or not further substituted in
349 the indene ring to any extent and whether or not substituted in
350 the naphthyl ring to any extent. This shall include, but not be
351 limited to, JWH 176.

352 (59) Phenylacetylindoles or any compound containing a 3-
353 Phenylacetylindole structure with substitution at the nitrogen
354 atom of the indole ring whether or not further substituted in the
355 indole ring to any extent and whether or not substituted in the
356 phenyl ring to any extent. This shall include the following:

357 (A) RCS-8, SR-18 OR BTM-8;

358 (B) JWH 250;

359 (C) JWH 203;

360 (D) JWH 251;

361 (E) JWH 302.

362 (60) Cyclohexylphenols or any compound containing a 2-(3-
363 hydroxycyclohexyl) phenol structure with a substitution at the 5-
364 position of the phenolic ring whether or not substituted in the
365 cyclohexyl ring to any extent. This shall include the following:

366 (A) CP 47,497 and its homologues and analogs;

367 (B) Cannabicyclohexanol;

368 (C) CP 55,940.

369 (61) Benzoylindoles or any compound containing a 3-
370 (benzoyl) indole structure with substitution at the nitrogen atom
371 of the indole ring whether or not further substituted in the indole
372 ring to any extent and whether or not substituted in the phenyl
373 ring to any extent. This shall include the following:

374 (A) AM 694;

375 (B) Pravadoline WIN 48,098;

376 (C) RCS 4;

377 (D) AM 679.

378 (62) [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo
379 [1,2,3-DE]-1,4-benzoxazin-6-YL]-1-napthalenymethanone. This
380 shall include WIN 55,212-2.

381 (63) Dibenzopyrans or any compound containing a 11-
382 hydroxydelta 8-tetrahydrocannabinol structure with substitution
383 on the 3-pentyl group. This shall include HU-210, HU-211, JWH
384 051 and JWH 133.

385 (64) Adamantoylindoles or any compound containing a 3-(-
386 1- Adamantoyl) indole structure with substitution at the nitrogen
387 atom of the indole ring whether or not further substituted in the
388 adamantoyl ring system to any extent. This shall include
389 AM1248.

390 (65) Tetramethylcyclopropylindoles or any compound
391 containing A 3-tetramethylcyclopropylindole structure with
392 substitution at the nitrogen atom of the indole ring whether or
393 not further substituted in the indole ring to any extent and
394 whether or not substituted in the tetramethylcyclopropyl ring to
395 any extent. This shall include UR-144 and XLR-11.

396 (66) N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide.
397 This shall include AKB48.

398 (67) Any other synthetic chemical compound that is a
399 Cannabinoid receptor type 1 agonist as demonstrated by binding
400 studies and functional assays that is not listed in Schedules II,
401 III, IV and V, not federal Food and Drug Administration
402 approved drug or used within legitimate, approved medical
403 research. Since nomenclature of these substances is not
404 internationally standardized, any immediate precursor or
405 immediate derivative of these substances shall be covered.

406 (68) Tryptamines:

407 (A) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-
408 MiPT)

409 (B) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT)

410 (C) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-
411 MiPT)

412 (D) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)

413 (E) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT)

414 (F) 5-methoxy- α -methyltryptamine (5-MeO-AMT)

415 (G) 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT)

416 (H) 4-hydroxy Diethyltryptamine (4-HO-DET)

417 (I) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT)

418 (J) 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT)

419 (K) 4-hydroxy Diethyltryptamine (4-HO-DET)

420 (e) *Depressants*. — Unless specifically excepted or unless
421 listed in another schedule, any material, compound, mixture, or
422 preparation which contains any quantity of the following
423 substances having a depressant effect on the central nervous
424 system, including its salts, isomers and salts of isomers
425 whenever the existence of such salts, isomers and salts of
426 isomers is possible within the specific chemical designation:

427 (1) Mecloqualone;

428 (2) Methaqualone.

429 (f) *Stimulants*. — Unless specifically excepted or unless
430 listed in another schedule, any material, compound, mixture, or
431 preparation which contains any quantity of the following
432 substances having a stimulant effect on the central nervous
433 system, including its salts, isomers and salts of isomers:

434 (1) Aminorex; some other names: aminoxaphen; 2-amino-5-
435 phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine;

436 (2) Cathinone; some trade or other names: 2-amino-1-
437 phenyl-1- propanone, alpha-aminopropiophenone, 2-
438 aminopropiophenone and norephedrone;

439 (3) Fenethylamine;

440 (4) Methcathinone, its immediate precursors and immediate
441 derivatives, its salts, optical isomers and salts of optical isomers;
442 some other names: (2-(methylamino)-propiophenone; alpha-
443 (methylamino)propiophenone; 2-(methylamino)-1-
444 phenylpropan-1- one; alpha—methylaminopropiophenone;
445 monomethylpropion; 3,4-methylenedioxypropylamphetamine and/or
446 mephedrone; 3,4-methylenedioxypropylamphetamine (MPVD);
447 ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-
448 422; AL- 463 and UR1432;

449 (5) (+-) cis-4-methylaminorex; ((+)-cis-4,5-dihydro-4-
450 methyl- 5-phenyl-2-oxazolamine);

451 (6) N-ethylamphetamine;

452 (7) N,N-dimethylamphetamine; also known as N,N-alpha-
453 trimethylbenzethanamine; N,N-alpha-
454 trimethylphenethylamine.

455 (8) Alpha-pyrrolidinopropiophenone, also known as alpha-
456 PVP, optical isomers, salts and salts of isomers.

457 (9) Substituted amphetamines:

458 (A) 2-Fluoroamphetamine

459 (B) 3-Fluoroamphetamine

460 (C) 4-Fluoroamphetamine

461 (D) 2-chloroamphetamine

462 (E) 3-chloroamphetamine

463 (F) 4-chloroamphetamine

464 (G) 2-Fluoromethamphetamine

465 (H) 3-Fluoromethamphetamine

466 (I) 4-Fluoromethamphetamine

467 (J) 4-chloromethamphetamine

468 (g) Temporary listing of substances subject to emergency
469 scheduling. Any material, compound, mixture or preparation
470 which contains any quantity of the following substances:

471 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
472 (benzylfentanyl), its optical isomers, salts, and salts of isomers.

473 (2) N-[1-(2-thienyl)methyl-4-piperidyl]-N-
474 phenylpropanamide (thenylfentanyl), its optical isomers, salts
475 and salts of isomers.

476 (3) N-benzylpiperazine, also known as BZP.

477 (h) The following controlled substances are included in
478 Schedule I:

479 (1) Synthetic Cathinones or any compound, except
480 bupropion or compounds listed under a different schedule, or
481 compounds used within legitimate and approved medical
482 research, structurally derived from 2- Aminopropan-1-one by
483 substitution at the 1-position with Monocyclic or fused
484 polycyclic ring systems, whether or not the compound is further
485 modified in any of the following ways:

486 (A) By substitution in the ring system to any extent with
487 Alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl or halide

488 Substituents whether or not further substituted in the ring system
489 by one or more other univalent substituents.

490 (B) By substitution at the 3-position with an acyclic alkyl
491 substituent.

492 (C) By substitution at the 2-amino nitrogen atom with alkyl,
493 dialkyl, benzyl or methoxybenzyl groups.

494 (D) By inclusion of the 2-amino nitrogen atom in a cyclic
495 structure.

496 (2) Any other synthetic chemical compound that is a
497 Cannabinoid receptor type 1 agonist as demonstrated by binding
498 studies and functional assays that is not listed in Schedules II,
499 III, IV and V, not federal Food and Drug Administration
500 approved drug or used within legitimate, approved medical
501 research.

That Joint Committee on Enrolled Bills hereby certifies that the foregoing bill is correctly enrolled.

Chairman, House Committee

Chairman, Senate Committee

Originating in the House.

In effect ninety days from passage.

Clerk of the House of Delegates

Clerk of the Senate

Speaker of the House of Delegates

President of the Senate

The within _____ this the _____
day of _____, 2015.

Governor

